Skip to main content
OSUR logo

OSUR · Orasure Technologies Inc

Track OSUR — free
$3.59 +0.08 (+2.28%) At close · Nov 18
Market Cap
$247.88M
Shares
69.05M
Volume · Nov 18 488.69K Avg daily vol (3M) 577.04K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.59 Open$3.51 Day$3.51–3.64 52W close$2.11–4.50 Avg vol 30d627K Short int2.6M · 3.8% of shares · 3.6d Short vol60% Last earningsNov 9, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 9

Up next

Feb 24, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 12
Quarterly report 10-Q/A FY2026 Q3, ended Sep 30
Quarterly revenue rises 14% as operating loss narrows

OraSure Technologies, Inc. said consolidated net revenues increased 14% to $30.9 million for the three months ended September 30, 2026, while operating loss narrowed to $13.0 million from $16.1 million.

Revenue $30.91M ▲ 14.1% Net loss $13.09M Diluted EPS -$0.19
Read from the MD&A section
3 source passages
ORASURE TECHNOLOGIES, INC. Consolidated net revenues increased 14% to $30.9 million for the three months ended September 30, 2026, from $27.1 million for the three months ended September 30, 2025. Consolidated operating loss for the three months ended September 30, 2026 was $13.0 million compared to an operating loss of $16.1 million for the three months ended September 30, 2025. Open the document at this passage
Nov 9
Earnings call
Cash-flow break-even expected in second half of 2027

Orashure Technologies reported third-quarter revenue of $30.9 million, up 14% year-over-year, and now expects operating cash-flow break-even in the second half of 2027 instead of entering 2027.

4 source passages
Good afternoon, and welcome to Orashure Technologies' third quarter 2026 earnings call. Total revenue in the third quarter was $30.9 million, growing 14% year-over-year and approximately 1% on a sequential basis. At the beginning of the year, we laid out a path to achieving cash flow from operations break-even entering 2027. we now expect to reach cash flow from operations break-even in the second half of 2027. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises 14% as operating loss narrows

OraSure Technologies reported net revenues of $30.9 million, up 14%, and an operating loss of $13.0 million versus $16.1 million. In June 2026, it received FDA 510(k) clearance for its Colli-Pee™•Dx Urine Collection Kit.

Revenue $30.91M ▲ 14.1% Net loss $13.09M Diluted EPS -$0.19
Read from the MD&A section
4 source passages
Consolidated net revenues increased 14% to $30.9 million for the three months ended September 30, 2026, from $27.1 million for the three months ended September 30, 2025. Consolidated operating loss for the three months ended September 30, 2026 was $13.0 million compared to an operating loss of $16.1 million for the three months ended September 30, 2025. In June 2026, the Company received FDA 510(k) clearance for its Colli-Pee™•Dx Urine Collection Kit, a prescription device for the at-home self-collection of first-void urine for use with FDA-cleared sexually transmitted infection (STI) molecular assays with which the device has been validated. OraSure Technologies, Inc. Open the document at this passage
Nov 9
Current report 8-K
Third-quarter revenue grew 14%, gross margin reached 45.2%

OraSure Technologies announced third-quarter 2026 revenue of $30.9 million, up 14% year-over-year, with GAAP gross margin of 45.2% and GAAP net loss of $13.1 million. It guided Q4 2026 revenue from $30.0 million to $32.0 million.

Financial results
5 source passages
OraSure Technologies, Inc. (Nasdaq: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended September 30, 2026. •Total net revenues for the third quarter of 2026 of $30.9 million grew 1% sequentially and increased 14% year-over-year. •GAAP gross margin was 45.2% in the third quarter of 2026 compared to 43.5% in the third quarter of 2025. •GAAP net loss in the third quarter of 2026 was $13.1 million compared to a GAAP net loss of $13.7 million in the third quarter of 2025. The Company is guiding to Q4 2026 total revenues of $30.0 million to $32.0 million. Open the document at this passage
Aug 7
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $30.64M ▼ 1.9% Net income $6.25M Diluted EPS $0.09
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$116.23M
Trailing 12 months
Net income (TTM)
−$48.51M
Trailing 12 months
Revenue growth YoY
+14.1%
Year over year
Operating margin
-43.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-20.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-5.5%
Year over year · fewer shares
Price change (1Y)
+69.3%
Trailing year
Short interest
3.8%
Latest settlement · 3.6 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 9, 2026
Q3 FY26

TL;DR. Q3 delivered 14% revenue growth, meaningful gross-margin expansion, lower operating spend, strong segment growth, and initial orders from two product launches, while management expects revenue growth to accelerate in 2027. The company remained loss-making and cash-consuming, and management expects cash-flow-from-operations break-even in the second half of 2027.

Bullish
  • + Q3 revenue grew 14% year-over-year and approximately 1% sequentially to $30.9 million.
  • + GAAP gross margin expanded 173 basis points to 45.2%, while non-GAAP gross margin increased to 45.9%.
  • + Operating spend improved materially on a sequential basis.
  • + Diagnostics revenue increased 16% to $16.8 million and Sample Management Solutions revenue increased 21% to $12.5 million.
  • + The Colli-Pee Dx and OraQuick Ebola 2.0 launches generated initial orders in Q3.
  • + Management expects full-year revenue growth to accelerate in 2027 from 2026.
Bearish
  • − Q3 operating cash flow was negative $10.9 million.
  • − Cash-flow-from-operations break-even was originally planned for entering 2027 but is now expected in the second half of 2027.
  • − The CT&G test remained in the FDA pre-submission process following its August submission withdrawal.
  • − GAAP net loss was $13.1 million in Q3 2026 versus $13.7 million in Q3 2025.
  • − Q4 gross margin was expected to be similar to or slightly below Q3.
  • − Adoption occurs through African-led, country-specific pathways for evaluation, registration, procurement, and deployment, and these new processes are taking time even during an urgent outbreak.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +1%
above
Price vs 50-day avg −4%
below
RSI (14) 47
neutral
MACD trend Negative
52-week position 62%
mid-range
Momentum
relative strength
Weak
1-month return −7%
trailing
6-month return −17%
trailing
YTD return +48%
this year
Relative strength −13%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow Distributing
-4% holders QoQ · +18 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.78% of shares out · ▼ -4.4% MoM · 3.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
146 holders — mid 3-yr range
Squeeze score 48
elevated · 0–100
Fundamentals
Fair
Revenue growth +30%
Y/Y
Gross margin 29%
contracting
EPS growth −262%
Y/Y
Free cash flow $-53.2M
Buyback $18.0M
remaining
Quant / Vol
risk profile
Very High
Volatility 50%
annualized · 1-yr
Max drawdown −28%
past year
ATR 5.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 8 of last 8
Latest guidance · from the Earnings Call filed Nov 9, 2026
In the fourth quarter
Revenue $30M – $32M
prior qtr $30.91M midpoint +0.3% QoQ
full-year 2026
Full-year revenue $119.5M – $121.5M
prior FY $115.02M midpoint +4.8% Y/Y
Previous outlook earlier release · from the Earnings Call filed Aug 5, 2026

Still-open targets the latest release did not restate under the same label.

Revenue · third quarter $29.5M – $32.5M
Prior guidance period ended · from the Earnings Call filed Aug 5, 2026
Revenue · third quarter of 2026 $29.5M – $32.5M
Guided vs delivered · last 8 settled
Revenue third quarter of 2026
guided $29.5M – $32.5M
$30.91M In line
Total Revenue Q2
guided $27M – $30M
$30.64M Beat +7.5%
Total revenues Q1 2026
guided $26M – $29M
$27.93M In line
Total revenue fourth quarter
guided $25M – $28M
$26.76M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+1% Bullish
Price vs 50-day avg
−4% Neutral
RSI (14)
47 Neutral
MACD trend
Negative Bearish
52-week position
62% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow Distributing
-4% holders QoQ · +18 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.78% of shares out · ▼ -4.4% MoM · 3.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
146 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2 Now $4 · 62% Range high $5
vs 200-day avg +1% vs 50-day avg -4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Core revenues 30.9M the third quarter of 2026 —
Diagnostics revenues 16.8M the third quarter of 2026 —
Non-GAAP Cost of Goods Sold non-GAAP 49.62M nine months ended September 30, 2026 —
Non-GAAP Gross Margin non-GAAP 44.5% nine months ended September 30, 2026 —
Non-GAAP gross profit non-GAAP 14.19M the third quarter of 2026 —
Non-GAAP Loss Per Share non-GAAP -$0.59 nine months ended September 30, 2026 —
Non-GAAP Net Loss non-GAAP -40.89M nine months ended September 30, 2026 —
Non-GAAP operating loss non-GAAP -43.99M the nine months ended September 30, 2026 —
Non-GAAP operating margin non-GAAP -33% the third quarter of 2026 —
Sample Management Solutions revenues 12.5M the third quarter of 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
OSUR
Orasure Technologies Inc
this stock
$247.88M +48.3% +30.3% — 3.8%
ISRG
Intuitive Surgical Inc
$145.92B -25.7% +20.5% 51.0 2.0%
BDX
Becton Dickinson & Co
$58.86B — +8.2% 95.6 3.0%
MDLN
Medline Inc.
$51.51B -6.8% +11.5% — 2.9%
ALC
Alcon Inc
$36.15B -4.5% +10.5% — 3.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
146
% held
82.4%
Net QoQ
+2.1M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
156
View
Short & Settlement
Short Interest Falling
Shares short
2.6M
Days to cover
3.6d
Change
-118.8K sh
View
Short Volume
Short vol %
60%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
1.1K
Value
$4.2K
As of
Oct 23, 2026
View
Off-Exchange
Off-exchange %
41.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Tom Malinowski
Amount
$15.0K–$50.0K
Traded
Feb 23, 2021
View
Financials
Financials
Revenue (FY)
$115.0M
Net income (FY)
$-68.7M
EPS diluted
$-0.94
View
Buybacks
Authorized
$40.0M
Remaining
$18.0M
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q/A
Filed
Nov 12, 2026
This year
23

OraSure Technologies, Inc. said consolidated net revenues increased 14% to $30.9 million for the three months ended September 30, 2026, while operating loss narrowed to $13.0 million from $16.1 million.

View
Proposed Sales
Value
$225.0K
Shares
89.7K
Filed
Dec 4, 2025
View
Earnings & Events
Webcasts
Last webcast
Nov 9, 2026
View
Investor Relations
Latest news
OraSure Announces Third Quarter 2…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
OSUR +0.8% -7.0% -16.5% -8.9% +48.4%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY +4.7% -1.4% -13.0% -5.5% +41.3%

Capital returns

Buyback program · as of Jun 30, 2026
Authorized
$40.00M
Spent (derived)
$22.00M
Remaining
$18.00M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1116463 CUSIP 68554V108 13F (30d) 162 filings 141 filers Visit website